🇺🇸 FDA
Patent

US 11306150

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

granted A61KA61K45/06A61P

Quick answer

US patent 11306150 (Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist) held by Five Prime Therapeutics, Inc. expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K45/06, A61P, A61P35/00